Patents by Inventor Shimiao Wang

Shimiao Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heteroaryl Dihydroindolones as Kinase Inhibitors
    Publication number: 20110257238
    Abstract: The present invention provides a compound represented by the formula: wherein the variables R1, b, R6, Y, Z, X, R and a are defined in the specification. Said compound may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, wherein said disease is selected from the group consisting of cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.
    Type: Application
    Filed: June 1, 2011
    Publication date: October 20, 2011
    Applicant: ALLERGAN, INC.
    Inventors: Sougato Boral, Xialing Guo, Shimiao Wang, Julie A. Wurster, Thomas C. Malone
  • Heteroaryl dihydroindolones as kinase inhibitors
    Patent number: 7977351
    Abstract: The present invention provides a compound represented by the formula: wherein the variables R1, b, R6, Y, Z, X, R and a are defined in the specification. Said compound may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, wherein said disease is selected from the group consisting of cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: July 12, 2011
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Xialing Guo, Shimiao Wang, Julie A. Wurster, Thomas C. Malone
  • Sulfoximines as kinase inhibitors
    Patent number: 7915443
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: March 29, 2011
    Assignee: Allergan, Inc.
    Inventors: Julie A. Wurster, Clarence Eugene Hull, III, Richard C. Yee, Sougato Boral, Shimiao Wang, Thomas C. Malone
  • SULFOXIMINES AS KINASE INHIBITORS
    Publication number: 20090099181
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: November 16, 2007
    Publication date: April 16, 2009
    Inventors: Julie A. Wurster, Clarence Eugene Hull, III, Richard C. Yee, Sougato Boral, Shimiao Wang, Thomas C. Malone
  • HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS
    Publication number: 20080045526
    Abstract: The present invention provides a compound represented by the formula: wherein the variables R1, b, R6, Y, Z, X, R and a are defined in the specification. Said compound may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, wherein said disease is selected from the group consisting of cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.
    Type: Application
    Filed: March 16, 2007
    Publication date: February 21, 2008
    Inventors: Sougato Boral, Xialing Guo, Shimiao Wang, Julie A. Wurster, Thomas C. Malone
  • (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
    Patent number: 7060844
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: April 1, 2003
    Date of Patent: June 13, 2006
    Assignee: Allergan, Inc.
    Inventors: Steven W. Andrews, Xialing Guo, Zhen Zhu, Clarence E. Hull, III, Julie A. Wurster, Shimiao Wang, Edward H. Wang, Thomas Malone
  • (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
    Publication number: 20060004084
    Abstract: The present invention relates to organic, molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: July 12, 2005
    Publication date: January 5, 2006
    Inventors: Steven Andrews, Xialing Guo, Zhen Zhu, Clarence Hull, Julie Wurster, Shimiao Wang, Edward Wang, Thomas Malone
  • (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
    Publication number: 20040019098
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: April 1, 2003
    Publication date: January 29, 2004
    Applicant: Allergan, Inc.
    Inventors: Steven W. Andrews, Xialing Guo, Zhen Zhu, Clarence E. Hull, Julie A. Wurster, Shimiao Wang, Edward H. Wang, Thomas Malone